Scandion Oncology strengthens executive leadership appointing Bo Rode Hansen as CEO and Nils Brünner as new CSO
Scandion Oncology appoints Bo Rode Hansen as new President & CEO and co-founder Nils Brünner as new CSO to strengthen executive leadership, and secure corporate- and pipeline development towards upcoming value inflection points for Scandion Oncology.
Scandion Oncology is pleased to announce that Bo Rode Hansen from October 1st is appointed President & CEO of the company. This planned evolution in the leadership of Scandion Oncology is executed to allow co-founder, Nils Brünner to focus his time, and world-renowned oncology expertise on the continued clinical development of our pipeline and to further strengthen our technology platform DEN50-R. The change provides the right balance and strength in the executive management team to bring Scandion Oncology to the next level of its corporate, scientific and pipeline development.
Dr. Peter Høngaard Andersen, Chairman of the Board: “We are now taking a major step in the transformation process of Scandion Oncology from an early stage biotech to a mature, clinical stage company. The positive data from the first patient cohort made it possible for us to attract a major international biotech profile like Bo Rode Hansen and I’m confident that Bo and Nils will drive Scandion Oncology towards commercial success to the benefit of patients and shareholders” states Dr. Høngaard Andersen and continues “we are at a stage where we are gearing up to initiate our second phase 2 study with SCO-101, prepare our second pipeline drug, SCO-201 for first human dose and further strengthen our technology platform DEN50-R. Simultaneously, we are also increasing our Business development activities and this increased activity level requires a stronger executive management team which we have now in place with Bo and Nils. The Board and I are very much looking forward to a continued collaboration with this strengthened team.
The new President & CEO, Dr. Bo Rode Hansen is a seasoned top executive and life science entrepreneur with decades of leadership experience from both Scandinavian and international pharma and biotech (Santaris Pharma (DK), Roche (CH) and Genevant Sciences (US)). He is bringing the right experience to balance specific skills within R&D strategy, partnering, M&A, corporate development and financing.
Bo Rode Hansen:
“I am very excited to join Nils and the Scandion Oncology team. The team and the board have done a stellar job in bringing Scandion Oncology to where it is today. Having had cancer in my family, I’m highly motivated to make a difference for the many cancer patients who will acquire resistance to existing cancer therapies; this is a large motivation for me. This area of medicine is challenging, and we need new therapies to improve survival of cancer patients. In that light I am impressed with the progress Scandion Oncology has made in this area. I am very pleased and optimistic to see the initial results from the ongoing clinical trial and with the emerging pipeline - spearheaded by SCO-101 - which for me materialized the opportunity and interest to join Scandion Oncology.”
I wholeheartedly welcome Bo Rode Hansen as the new CEO of Scandion Oncology. Bo has the needed business and scientific background to take Scandion Oncology forward. Personally, I am looking forward to getting the needed time to be fully involved with our preclinical and clinical teams. When I in 2018 accepted the position as CEO of Scandion Oncology it was a clear understanding that I wanted to be replaced as CEO when we had started the clinical phase II studies and initiated Business development. Scandion Oncology has now passed a number of significant clinical milestones and I think the time is perfect for Bo to take the wheel.
We have an interview with Bo and Nils on our homepage www.scandiononcology.com
For further information regarding Scandion Oncology, please contact:
Bo Rode Hansen, Phone: + 45 28 34 08 71; e-mail: email@example.com
Nils Brünner, Phone: +45 26 14 47 08; e-mail: firstname.lastname@example.org
This information is information that Scandion Oncology is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on September 16, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.